Life Sciences Opportunities in India & China: From Innovation to Commercialization
September 30, 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Panelists:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Related Insights
June 18, 2025
Energy Current
Texas Energizes Nuclear Energy Strategy with Passage of Three Key Bills
The Texas Legislature recently passed three key bills: House Bill 14 (H.B. 14); Senate Bill 1061 (S.B. 1061); and Senate Bill 1535 (S.B….
June 18, 2025
Energy Current
FERC Issues Guidance on Treatment of Criminal Regulatory Offenses
On June 16, 2025, the Federal Energy Regulatory Commission (FERC) issued a Notice of Guidance regarding the consistency of its existing…
June 18, 2025
Foley Viewpoints
Legal Reasoning Still a Struggle for LLMs
The authors in this paper created a benchmark including long-form, open-ended questions and multiple-choice questions to evaluate the…